CD81 is a novel immunotherapeutic target for B cell lymphoma

CD81 is a novel immunotherapeutic target for B cell lymphoma

The tetraspanin was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target , has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of experimental medicine 2019-07, Vol.216 (7), p.1497-1508
Hauptverfasser: Vences-Catalán, Felipe, Kuo, Chiung-Chi, Rajapaksa, Ranjani, Duault, Caroline, Andor, Noemi, Czerwinski, Debra K, Levy, Ronald, Levy, Shoshana
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1508
container_issue 7
container_start_page 1497
container_title The Journal of experimental medicine
container_volume 216
creator Vences-Catalán, Felipe
Kuo, Chiung-Chi
Rajapaksa, Ranjani
Duault, Caroline
Andor, Noemi
Czerwinski, Debra K
Levy, Ronald
Levy, Shoshana
description The tetraspanin was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target , has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.
doi_str_mv 10.1084/jem.20190186
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6605745</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2232127350</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-cf53997a930a5e9af8c1911297e4ca2982b1b86d5060ecee3d857c773218df833</originalsourceid><addsrcrecordid>eNpVkM1LxDAQxYMoun7cPEuOHqxOkqZNQARdP2HBi55DNp3udmmaNWkF_3u7-IGe5jBv3nvzI-SYwTkDlV-s0J9zYBqYKrbIhMkcMi2F2iYTAM4zBlDukf2UVgAsz2WxS_YEY1yMxxNyOb1VjDaJWtqFd2xp4_3QhX6J0a5x6BtHexsX2NM6RHpDHbYtbT_8ehm8PSQ7tW0THn3PA_J6f_cyfcxmzw9P0-tZ5nIJfeZqKbQurRZgJWpbK8f02ECXmDvLteJzNldFJaEAdIiiUrJ0ZSk4U1WthDggV1--62HusXLY9dG2Zh0bb-OHCbYx_zddszSL8G6KAmSZy9Hg9NsghrcBU298kzav2A7DkAznYxYvhYRRevYldTGkFLH-jWFgNsDNCNz8AB_lJ3-r_Yp_CItPQs57LA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2232127350</pqid></control><display><type>article</type><title>CD81 is a novel immunotherapeutic target for B cell lymphoma</title><source>Free E-Journal (出版社公開部分のみ）</source><creator>Vences-Catalán, Felipe ; Kuo, Chiung-Chi ; Rajapaksa, Ranjani ; Duault, Caroline ; Andor, Noemi ; Czerwinski, Debra K ; Levy, Ronald ; Levy, Shoshana</creator><creatorcontrib>Vences-Catalán, Felipe ; Kuo, Chiung-Chi ; Rajapaksa, Ranjani ; Duault, Caroline ; Andor, Noemi ; Czerwinski, Debra K ; Levy, Ronald ; Levy, Shoshana</creatorcontrib><description>The tetraspanin was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target , has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.</description><identifier>ISSN: 0022-1007</identifier><identifier>EISSN: 1540-9538</identifier><identifier>DOI: 10.1084/jem.20190186</identifier><identifier>PMID: 31123084</identifier><language>eng</language><publisher>United States: Rockefeller University Press</publisher><ispartof>The Journal of experimental medicine, 2019-07, Vol.216 (7), p.1497-1508</ispartof><rights>2019 Vences-Catalán et al.</rights><rights>2019 Vences-Catalán et al. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-cf53997a930a5e9af8c1911297e4ca2982b1b86d5060ecee3d857c773218df833</citedby><cites>FETCH-LOGICAL-c450t-cf53997a930a5e9af8c1911297e4ca2982b1b86d5060ecee3d857c773218df833</cites><orcidid>0000-0001-7837-6911</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31123084$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vences-Catalán, Felipe</creatorcontrib><creatorcontrib>Kuo, Chiung-Chi</creatorcontrib><creatorcontrib>Rajapaksa, Ranjani</creatorcontrib><creatorcontrib>Duault, Caroline</creatorcontrib><creatorcontrib>Andor, Noemi</creatorcontrib><creatorcontrib>Czerwinski, Debra K</creatorcontrib><creatorcontrib>Levy, Ronald</creatorcontrib><creatorcontrib>Levy, Shoshana</creatorcontrib><title>CD81 is a novel immunotherapeutic target for B cell lymphoma</title><title>The Journal of experimental medicine</title><addtitle>J Exp Med</addtitle><description>The tetraspanin was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target , has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.</description><issn>0022-1007</issn><issn>1540-9538</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpVkM1LxDAQxYMoun7cPEuOHqxOkqZNQARdP2HBi55DNp3udmmaNWkF_3u7-IGe5jBv3nvzI-SYwTkDlV-s0J9zYBqYKrbIhMkcMi2F2iYTAM4zBlDukf2UVgAsz2WxS_YEY1yMxxNyOb1VjDaJWtqFd2xp4_3QhX6J0a5x6BtHexsX2NM6RHpDHbYtbT_8ehm8PSQ7tW0THn3PA_J6f_cyfcxmzw9P0-tZ5nIJfeZqKbQurRZgJWpbK8f02ECXmDvLteJzNldFJaEAdIiiUrJ0ZSk4U1WthDggV1--62HusXLY9dG2Zh0bb-OHCbYx_zddszSL8G6KAmSZy9Hg9NsghrcBU298kzav2A7DkAznYxYvhYRRevYldTGkFLH-jWFgNsDNCNz8AB_lJ3-r_Yp_CItPQs57LA</recordid><startdate>20190701</startdate><enddate>20190701</enddate><creator>Vences-Catalán, Felipe</creator><creator>Kuo, Chiung-Chi</creator><creator>Rajapaksa, Ranjani</creator><creator>Duault, Caroline</creator><creator>Andor, Noemi</creator><creator>Czerwinski, Debra K</creator><creator>Levy, Ronald</creator><creator>Levy, Shoshana</creator><general>Rockefeller University Press</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7837-6911</orcidid></search><sort><creationdate>20190701</creationdate><title>CD81 is a novel immunotherapeutic target for B cell lymphoma</title><author>Vences-Catalán, Felipe ; Kuo, Chiung-Chi ; Rajapaksa, Ranjani ; Duault, Caroline ; Andor, Noemi ; Czerwinski, Debra K ; Levy, Ronald ; Levy, Shoshana</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-cf53997a930a5e9af8c1911297e4ca2982b1b86d5060ecee3d857c773218df833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vences-Catalán, Felipe</creatorcontrib><creatorcontrib>Kuo, Chiung-Chi</creatorcontrib><creatorcontrib>Rajapaksa, Ranjani</creatorcontrib><creatorcontrib>Duault, Caroline</creatorcontrib><creatorcontrib>Andor, Noemi</creatorcontrib><creatorcontrib>Czerwinski, Debra K</creatorcontrib><creatorcontrib>Levy, Ronald</creatorcontrib><creatorcontrib>Levy, Shoshana</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of experimental medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vences-Catalán, Felipe</au><au>Kuo, Chiung-Chi</au><au>Rajapaksa, Ranjani</au><au>Duault, Caroline</au><au>Andor, Noemi</au><au>Czerwinski, Debra K</au><au>Levy, Ronald</au><au>Levy, Shoshana</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD81 is a novel immunotherapeutic target for B cell lymphoma</atitle><jtitle>The Journal of experimental medicine</jtitle><addtitle>J Exp Med</addtitle><date>2019-07-01</date><risdate>2019</risdate><volume>216</volume><issue>7</issue><spage>1497</spage><epage>1508</epage><pages>1497-1508</pages><issn>0022-1007</issn><eissn>1540-9538</eissn><abstract>The tetraspanin was initially discovered by screening mAbs elicited against a human B cell lymphoma for their direct antiproliferative effects. We now show that 5A6, one of the mAbs that target , has therapeutic potential. This antibody inhibits the growth of B cell lymphoma in a xenograft model as effectively as rituximab, which is a standard treatment for B cell lymphoma. Importantly, unlike rituximab, which depletes normal as well as malignant B cells, 5A6 selectively kills human lymphoma cells from fresh biopsy specimens while sparing the normal lymphoid cells in the tumor microenvironment. The 5A6 antibody showed a good safety profile when administered to a mouse transgenic for human CD81. Taken together, these data provide the rationale for the development of the 5A6 mAb and its humanized derivatives as a novel treatment against B cell lymphoma.</abstract><cop>United States</cop><pub>Rockefeller University Press</pub><pmid>31123084</pmid><doi>10.1084/jem.20190186</doi><tpages>12</tpages><orcidid>https://orcid.org/0000-0001-7837-6911</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0022-1007
ispartof The Journal of experimental medicine, 2019-07, Vol.216 (7), p.1497-1508
issn 0022-1007
1540-9538
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6605745
source Free E-Journal (出版社公開部分のみ）
title CD81 is a novel immunotherapeutic target for B cell lymphoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T15%3A00%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD81%20is%20a%20novel%20immunotherapeutic%20target%20for%20B%20cell%20lymphoma&rft.jtitle=The%20Journal%20of%20experimental%20medicine&rft.au=Vences-Catal%C3%A1n,%20Felipe&rft.date=2019-07-01&rft.volume=216&rft.issue=7&rft.spage=1497&rft.epage=1508&rft.pages=1497-1508&rft.issn=0022-1007&rft.eissn=1540-9538&rft_id=info:doi/10.1084/jem.20190186&rft_dat=%3Cproquest_pubme%3E2232127350%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2232127350&rft_id=info:pmid/31123084&rfr_iscdi=true